Related Experiment Videos
Recombinant human granulocyte colony-stimulating factor therapy for cyclic neutropenia associated with common
M Tsuda1, T Urakami, S Watanabe
1Department of Pediatrics, Nihon University, School of Medicine, Tokyo, Japan.
Insights
This study investigated recombinant human granulocyte colony-stimulating factor (rhG-CSF) for a boy with common variable immunodeficiency and cyclic neutropenia. While rhG-CSF increased neutrophil counts, it did not alter the cyclic pattern, suggesting variable efficacy.
Area of Science:
- Pediatric Immunology
- Hematology
Background:
- Common variable immunodeficiency (CVID) can present with recurrent infections.
- Cyclic neutropenia is a rare disorder characterized by periodic drops in neutrophil counts, increasing infection risk.
- Recombinant human granulocyte colony-stimulating factor (rhG-CSF) has shown promise in managing cyclic neutropenia.
Abstract:
A 14 year old boy with common variable immunodeficiency (CVID) had regularly recurring episodes of severe infections independently of the serum gamma-globulin level. Serial blood counts revealed that this patient also had cyclic neutropenia. Recently, recombinant human granulocyte colony-stimulating factor (rhG-CSF) was reported to be an effective treatment for this disease. We tried rhG-CSF therapy for this patient and a prompt increase in the neutrophil count was noted. However, the cyclic alterations and duration of the nadir of the neutrophil count were not altered, which suggested that rhG-CSF has a variable efficacy in at least some patients with cyclic neutropenia.